Pregnant Women With HIV Infection Can Expect Healthy Survival: Three-Year Follow-Up
November 3, 2006
Fabiola Martin of St. Mary's NHS Trust in London and colleagues followed up with 311 HIV-positive pregnant women who had given birth to assess their long-term health, Reuters Health reports (Reuters Health, 10/30). The researchers divided the women into three groups depending on their immune status. One group was treated with zidovudine monotherapy, the second group received highly active antiretroviral therapy during and after pregnancy, and a third group received short-term HAART during pregnancy only (Martin et al., JAIDS, 10/1). The average follow-up time was 33 months, according to Reuters Health. The study found that 98% of all the women survived through the last follow-up visit without progressing to AIDS. The study also found that three of the 85 women who received zidovudine monotherapy had disease progression; two of the 154 women who were treated with HAART during and after pregnancy had disease progression; and one of the 71 women who were treated with short-term HAART during pregnancy had disease progression. Researchers concluded that with access to HAART, teh progression to AIDS for women giving birth is uncommon, and it is possible to achieve a frequency of mother-to-child HIV transmission that is less than 1% (Reuters Health, 10/30).
Short-Term Risk of AIDS or Death in People Infected With HIV-1 Before Antiretroviral Therapy in South Africa: A Longitudinal Study
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.